NeoImmuneTech

Focus: NeoImmuneTech is an immunotherapy-focused biotech company headquartered in Rockville, MD, specializing in IL-7-based therapeutics for oncology and infectious diseases.

Oncology Infectious Diseases

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About NeoImmuneTech

AI assessmentNot Hiring

No open roles listed right now. Follow NeoImmuneTech to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

18 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

Double-Blind NT-I7

COVID-19

Phase 1

Clinical Trials (1)

NCT04501796A Trial of NT-I7 in COVID-19 (SPESELPIS)

Phase 1

Help build intelligence for NeoImmuneTech

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Lead pipeline asset NT-I7 has broad oncology and infectious disease application across 8+ indications with Phase 1/2 programs in melanoma, lymphomas, and solid tumors
Focused platform approach on IL-7-based immunotherapy reduces organizational complexity and increases depth of expertise in core mechanism
Early-stage discovery environment offers high scientific autonomy and direct impact on drug development for understudied indications like progressive multifocal leukoencephalopathy

Watch Out For

All 18 programs remain in Phase 1/2 with zero Phase 3 programs—no near-term regulatory milestones or revenue catalysts expected
No active job openings and missing data on employee count, funding status, and financial position creates uncertainty about growth trajectory and job security

Generated by Claude from NeoImmuneTech's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Recombinant human IL-7-hyFc

Breast Carcinoma

Phase 1

Clinical Trials (1)

NCT04054752Vaccine Response With NT-I7

Phase 1

NT-I7

Progressive Multifocal Leukoencephalopathy

Phase 1

Clinical Trials (1)

NCT04781309NT-I7, a Long-Acting Recombinant IL-7 Molecule, as an Immune Reconstitution Strategy for Lymphopenia in Patients With Progressive Multifocal Leukoencephalopathy

Phase 1

Laboratory Biomarker Analysis

Lymphopenia

Phase 1

Clinical Trials (1)

NCT02659800Study of the Effect NT-I7 on CD4 Counts in Patients With High Grade Gliomas

Phase 1

NT-I7

Multiple Myeloma

Phase 1

Clinical Trials (1)

NCT07200089Recombinant Human IL-7 (NT-I7) in Relapsed/Refractory Multiple Myeloma Following BCMA CAR-T Therapy (Cilta-cel)

Phase 1

NT-I7

Large B-cell Lymphoma

Phase 1

Clinical Trials (1)

NCT07052305NT-I7 (Efineptakin Alfa), a Long-acting Human IL-7, Post-Axicabtagene Ciloleucel or Post-Lisocabtagene Maraleucel in Subjects With Relapsed/Refractory Large B-cell Lymphoma

Phase 1

Efineptakin alfa

Refractory Diffuse Large B-cell Lymphoma

Phase 1

Clinical Trials (1)

NCT05075603Relapsed/Refractory Large B-cell Lymphoma With NT-I7 Post-CD19 CAR T-cell Therapy

Phase 1

Efineptakin alfa

Recurrent Head and Neck Squamous Cell Carcinoma

Phase 1

Clinical Trials (1)

NCT04588038NT-I7 for the Treatment of Recurrent Squamous Cell Carcinoma of Head and Neck Undergoing Surgery

Phase 1

NT-I7

COVID-19

Phase 1

Clinical Trials (1)

NCT04498325Evaluating the Effect of NT-I7, a Long Acting Interleukin-7, to Increase Lymphocyte Counts and Enhance Immune Clearance of SARS-CoV-2 (COVID-19)

Phase 1

NT-I7

Melanoma

Phase 1/2

Clinical Trials (1)

NCT03901573High-Risk Skin Cancers With Atezolizumab Plus NT-I7

Phase 1/2

rhIL-7-hyFc

Glioma

Phase 1/2

Clinical Trials (1)

NCT03687957rhIL-7-hyFc on Increasing Lymphocyte Counts in Patients With Newly Diagnosed Non-severe Lymphopenic Gliomas Following Radiation and Temozolomide

Phase 1/2

Recombinant human interleukin

Idiopathic CD4 Lymphopenia

Phase 1/2

Clinical Trials (1)

NCT05600920A Single-arm, Dose-escalation Trial of Long-acting Recombinant Human IL-7 (NT-I7, Efineptakin Alfa) for Idiopathic CD4 Lymphopenia

Phase 1/2

efineptakin alfa

Carcinoma, Non-Small-Cell Lung

Phase 2

Biospecimen Collection

High Grade Astrocytic Tumor